Nucleo CMP and Neurorubine Versus Carbamazepine for Classical Trigeminal Neuralgia

Summary

Trigeminal neuralgia is a severe facial pain condition that significantly impacts quality of life. While the standard medication, carbamazepine, provides relief, it is often associated with side effects and rapid pain recurrence upon discontinuation. This randomized clinical trial compares the efficacy and safety of conventional carbamazepine therapy against a novel combination therapy consisting of Nucleo CMP (cytidine monophosphate) and Neurorubine (Vitamin B complex). The study aims to evaluate pain reduction during active treatment and the sustainability of pain control after treatment cessation.

Timeline

Start

2024-01-07

Primary completion

2024-07-14

Completion

2024-09-30

Drugs

Indications